Bal et al. showed that CRISPR–Cas9-mediated correction of this mutation in LY10 DLBCL cell line leads to decreased BCL2 mRNA expression and dramatically decreased cell growth and survival, revealing oncogenic addiction of the cell-line to this mutation. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.